Press Releases
| Date ⇅ | Title ⇅ | Organisation ⇅ | Entities | Categories | Summary |
|---|---|---|---|---|---|
| 2025-11-08 | Amgen's Repatha Cuts Risk of First Major Adverse Cardiovascular Events by 25% in Landmark Phase 3 Vesalius-CV Trial | Amgen announced results from Phase 3 VESALIUS-CV evaluating Repatha (evolocumab) added to statin therapy in 12,000+ high-risk adults without prior ... |
Amgen's Repatha Cuts Risk of First Major Adverse Cardiovascular Events by 25% in Landmark Phase 3 Vesalius-CV Trial
Amgen announced results from Phase 3 VESALIUS-CV evaluating Repatha (evolocumab) added to statin therapy in 12,000+ high-risk adults without prior ...